Breast ductal adenocarcinoma
MONDO:0005590A breast carcinoma arising from the ducts. While ductal carcinomas can arise at other sites, this term is universally used to refer to carcinomas of the breast. Ductal carcinomas account for about two thirds of all breast cancers. Two types of ductal carcinomas have been described: ductal carcinoma in situ (DCIS) and invasive ductal carcinoma. The latter often spreads to the axillary lymph nodes and other anatomic sites. The two forms of ductal carcinoma often coexist.
Also known as: duct adenocarcinoma, duct carcinoma, ductal adenocarcinoma, ductal carcinoma, breast ductal carcinoma, ductal breast adenocarcinoma, ductal breast carcinoma, ductal carcinoma of breast
2989 clinical trials for this condition and its sub-types, 19 tagged with Breast ductal adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Breast ductal adenocarcinoma
-
Ductal breast carcinoma in situ 152 trials
1 sub-type
-
Invasive ductal breast carcinoma 41 trials · 48 incl. sub-types
10 sub-types
- Basal-like breast carcinoma 5 trials
- Invasive tubular breast carcinoma 5 trials
- Medullary breast carcinoma 2 trials
- Breast mucinous carcinoma 1 trial Sub-types →
- Breast secretory carcinoma 1 trial Sub-types →
- Acinic cell breast carcinoma 0 trials
- Glycogen-rich clear cell breast carcinoma 0 trials
- Invasive ductal and lobular carcinoma 0 trials
- Pleomorphic breast carcinoma 0 trials
- Scirrhous breast carcinoma 0 trials
-
Breast papillary carcinoma 1 trial
1 sub-type
- Solid papillary breast carcinoma 0 trials
-
Breast apocrine carcinoma 0 trials
Most studied deeper sub-types
-
Can an oral drug replace injections for advanced breast cancer?
Disease control CompletedResearchers are testing a new oral drug called rintodestrant (G1T48) in women with advanced breast cancer that is estrogen receptor-positive and HER2-negative. The trial gives the drug alone or with palbociclib, a standard breast cancer medicine. The main goals are to find a safe…
Phase 1 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
Can a targeted drug boost hormone therapy against breast cancer?
Disease control CompletedThis trial is testing whether adding an experimental drug called BYL719 to standard hormone therapy (letrozole) can better fight hormone receptor-positive metastatic breast cancer in post-menopausal women. BYL719 targets a protein that helps cancer cells grow, while letrozole blo…
Phase 1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Radiation may let breast cancer patients keep their nipple
Disease control CompletedThis trial tests whether giving radiation to the nipple and areola after a nipple-sparing mastectomy is safe and feasible for women with early-stage breast cancer. The goal is to see if this extra radiation can reduce the risk of cancer returning in the preserved nipple area, all…
Sponsor: University of Miami • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Breakthrough fertility method may keep estrogen low during cancer treatment
Disease control CompletedThis study tested a new ovarian stimulation protocol using degarelix (a drug typically used for prostate cancer) to help breast cancer patients preserve their fertility before chemotherapy. The goal was to keep estrogen levels low while still collecting enough eggs for freezing. …
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Cold sore virus turned cancer assassin shows promise in tough breast cancer
Disease control CompletedThis study tested whether injecting a modified herpes virus (T-VEC) directly into tumors, alongside standard chemotherapy before surgery, could better eliminate triple negative breast cancer. The virus is designed to infect and destroy cancer cells while leaving healthy cells alo…
Phase 1/2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a short course of radiation before surgery spare more breast tissue?
Disease control CompletedThis pilot study tested whether giving a high dose of focused radiation (APBI) to the tumor before surgery is feasible for older women with early-stage, hormone-sensitive breast cancer. Twenty-two participants received radiation followed by a lumpectomy. The goal was to see if th…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Glow-in-the-Dark dye could help surgeons spot hidden breast cancer
Diagnosis CompletedThis study tested a new imaging dye called LS301-IT in 22 women with early-stage breast cancer (DCIS or stage I-II) who were having a partial mastectomy. The dye is injected into a vein before surgery to make cancer cells glow, helping surgeons see and remove them more accurately…
Phase 1/2 • Sponsor: Integro Theranostics • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC